JP2005538034A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005538034A5 JP2005538034A5 JP2003550745A JP2003550745A JP2005538034A5 JP 2005538034 A5 JP2005538034 A5 JP 2005538034A5 JP 2003550745 A JP2003550745 A JP 2003550745A JP 2003550745 A JP2003550745 A JP 2003550745A JP 2005538034 A5 JP2005538034 A5 JP 2005538034A5
- Authority
- JP
- Japan
- Prior art keywords
- kit
- dose
- administration
- formulated
- week
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108010002350 Interleukin-2 Proteins 0.000 claims 89
- 102000000588 Interleukin-2 Human genes 0.000 claims 89
- 230000003442 weekly effect Effects 0.000 claims 17
- 210000002966 serum Anatomy 0.000 claims 13
- 210000004027 cell Anatomy 0.000 claims 10
- 238000011282 treatment Methods 0.000 claims 7
- 238000012423 maintenance Methods 0.000 claims 6
- 238000011284 combination treatment Methods 0.000 claims 5
- 210000000822 natural killer cell Anatomy 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims 4
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 102000055277 human IL2 Human genes 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1796801A | 2001-12-07 | 2001-12-07 | |
| US10/293,664 US20030185796A1 (en) | 2000-03-24 | 2002-11-12 | Methods of therapy for non-hodgkin's lymphoma |
| PCT/US2002/039253 WO2003049694A2 (en) | 2001-12-07 | 2002-12-06 | Methods of therapy for non-hodgkin's lymphoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005538034A JP2005538034A (ja) | 2005-12-15 |
| JP2005538034A5 true JP2005538034A5 (enExample) | 2006-11-30 |
Family
ID=26690566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003550745A Withdrawn JP2005538034A (ja) | 2001-12-07 | 2002-12-06 | 非ホジキンリンパ腫の治療方法 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1463524A4 (enExample) |
| JP (1) | JP2005538034A (enExample) |
| AU (1) | AU2002362098A1 (enExample) |
| CA (1) | CA2469045A1 (enExample) |
| WO (1) | WO2003049694A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR042485A1 (es) | 2002-12-16 | 2005-06-22 | Genentech Inc | Anticuerpo humanizado que se une al cd20 humano |
| NZ543712A (en) | 2003-06-05 | 2008-06-30 | Genentech Inc | Combination therapy for B cell disorders |
| US8147832B2 (en) * | 2003-08-14 | 2012-04-03 | Merck Patent Gmbh | CD20-binding polypeptide compositions and methods |
| EP1709196A4 (en) * | 2003-12-22 | 2008-10-29 | Novartis Vaccines & Diagnostic | USE OF FC RECEPTOR POLYMORPHISMS AS DIAGNOSTICS FOR TREATMENT STRATEGIES IN IMMUNE TELEPHONE DISORDERS |
| EP2425847A1 (en) | 2004-05-20 | 2012-03-07 | ZymoGenetics, Inc. | Methods of treating cancer using IL-21 and monoclonal antibody therapy |
| AU2005249566B2 (en) | 2004-06-04 | 2010-11-11 | Genentech, Inc. | Method for treating multiple sclerosis |
| WO2006089064A1 (en) * | 2005-02-15 | 2006-08-24 | Novartis Vaccines And Diagnostics Inc. | Methods for treating lymphomas using a combination of a chemotherapeutic agent and il-2 and optionally an anti-cd20 antibody |
| CN101223448B (zh) | 2005-05-20 | 2012-01-18 | 健泰科生物技术公司 | 来自自身免疫病受试者的生物学样品的预处理 |
| MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
| ES2618543T3 (es) | 2005-11-23 | 2017-06-21 | Genentech, Inc. | Métodos y composiciones relacionados con ensayos de linfocitos B |
| HUE046992T2 (hu) | 2007-07-09 | 2020-04-28 | Genentech Inc | Diszulfidkötés redukciójának megelõzése polipeptidek rekombináns elõállítása során |
| EP2200631A1 (en) | 2007-10-16 | 2010-06-30 | Zymogenetics, Inc. | Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease |
| EP2077281A1 (en) | 2008-01-02 | 2009-07-08 | Bergen Teknologioverforing AS | Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
| US7914785B2 (en) | 2008-01-02 | 2011-03-29 | Bergen Teknologieverforing As | B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
| ATE548052T1 (de) * | 2008-01-17 | 2012-03-15 | Philogen Spa | Kombination aus einem anti-edb-fibronectin- antikörper-il-2-fusionsprotein und einem b-zellen bindenden molekül, b-zellen-vorläufern und/oder deren krebserregendem gegenspieler |
| TW201438738A (zh) | 2008-09-16 | 2014-10-16 | Genentech Inc | 治療進展型多發性硬化症之方法 |
| WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
| SI2464725T2 (sl) | 2009-08-11 | 2025-06-30 | F. Hoffmann-La Roche Ag | Proizvodnja beljakovin v medijih za celične kulture brez glutamina |
| EP2533810B1 (en) | 2010-02-10 | 2016-10-12 | ImmunoGen, Inc. | Cd20 antibodies and uses thereof |
| UA123053C2 (uk) | 2015-06-24 | 2021-02-10 | Ф. Хоффманн-Ля Рош Аг | Антитіло до рецептора трансферину зі спеціально підібраною афінністю |
| MA43023A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Anticorps de récepteur de la transferrine humaine/anti-humaine cd20 bispécifique et leurs procédés d'utilisation |
| CN115369086B (zh) * | 2022-02-22 | 2023-05-12 | 北京景达生物科技有限公司 | 一种nk细胞扩大培养的培养方案 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001072333A1 (en) * | 2000-03-24 | 2001-10-04 | Chiron Corporation | Methods of therapy for non-hodgkin's lymphoma using a combination_of an antibody to cd20 and interleuking-2 |
-
2002
- 2002-12-06 CA CA002469045A patent/CA2469045A1/en not_active Abandoned
- 2002-12-06 EP EP02797231A patent/EP1463524A4/en not_active Withdrawn
- 2002-12-06 WO PCT/US2002/039253 patent/WO2003049694A2/en not_active Ceased
- 2002-12-06 AU AU2002362098A patent/AU2002362098A1/en not_active Abandoned
- 2002-12-06 JP JP2003550745A patent/JP2005538034A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005538034A5 (enExample) | ||
| JP6878524B2 (ja) | Ｉｌ−１７抗体の医薬製品および安定した液体組成物 | |
| Motzer et al. | Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. | |
| Oldenburg et al. | Induction of immune tolerance in haemophilia A inhibitor patients by the ‘Bonn Protocol ‘: predictive parameter for therapy duration and outcome | |
| CN100420482C (zh) | ω干扰素在制备用于治疗丙型肝炎的药物中的用途 | |
| Mori et al. | Tofacitinib therapy for rheumatoid arthritis: a direct comparison study between biologic-naïve and experienced patients | |
| RU2006120950A (ru) | Антитело к cd40: препарат и способы | |
| JP2006523682A5 (enExample) | ||
| JP2003528155A5 (enExample) | ||
| JP2014114288A5 (enExample) | ||
| CN112153982A (zh) | 用于通过施用il-4r抑制剂治疗特应性皮炎的方法 | |
| JP2023162351A (ja) | Ｉｌ－１７アンタゴニストを用いて化膿性汗腺炎を治療すること | |
| JP2022160685A5 (enExample) | ||
| JP2018515493A5 (enExample) | ||
| JP2025102888A (ja) | Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 | |
| JP2020100653A (ja) | ベンラリツマブによる喘息症状の改善方法 | |
| JP2009515994A5 (enExample) | ||
| Kragballe et al. | Unmet needs in the treatment of psoriasis | |
| Gensicke et al. | Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis | |
| JP7370357B2 (ja) | 医薬組成物 | |
| CN1946734B (zh) | 系统性治疗关节炎的组合物和方法 | |
| WO2021211927A1 (en) | Treatment of hidradenitis suppurativa | |
| AU2017363970A1 (en) | Methods of enhancing immune response with everolimus, dactolisib or both | |
| CN112533675A (zh) | 通过递送抗OSMRβ抗体治疗皮肤疾病或病症 | |
| JPWO2021123902A5 (enExample) |